Side-by-side comparison of AI visibility scores, market position, and capabilities
SF YC W20 school-based teletherapy for students with 60+ district partnerships; $25M total ($13M USV/Lux/Lightspeed Series B Aug 2023) competing with Hazel Health and Brightline for school district mental health access.
Daybreak Health is a San Francisco-based school-based teletherapy platform — backed by Y Combinator (W20) with $25 million in total funding including a $13 million Series B in August 2023 led by Union Square Ventures with Lux Capital, Lightspeed Venture Partners, Maven Ventures, and Y Combinator, following a $10 million Series A in 2022 and $1.8 million seed in 2021 — providing school districts with high-quality, affordable, and culturally competent virtual mental health therapy for students, partnering with 60+ school districts since 2019 to address the student mental health crisis through personalized counseling delivered by licensed therapists through telehealth. Founded in 2019, Daybreak positions as the leading school-based teletherapy provider focused on making mental health support accessible to all students regardless of socioeconomic status.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.